About Orano Med

Orano Med's ambition is to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb)
Find out more

Using the power of alpha emitters to fight cancer

Targeted Alpha Therapy: a powerful way to treat cancer
Find out more

A wide range of programs under development

Based on 212Pb unique properties, Orano Med is developing a multi asset portfolio with diverse biological vectors targeting different cancermarkers.
Find out more

Discover Orano Med and Targeted Alpha Therapy with 212Pb

Our latest News

  • Orano Med Presentations at the European Association of Nuclear Medicine (EANM) 2019 Annual Congress

  • Orano Med extends its production capacity in France and the USA

  • RadioMedix and Orano Med receive FDA orphan drug designation for AlphaMedix for the treatment of neuroendocrine tumors

By using this website, you agree with the cookies use. To get more information, manage or modify the cookies parameters on your computer, please read our Cookies Policy in the Legal Notice
I accept the cookies use